Cancer Expert MD

Fenbendazole is one of the most searched cancer topics on the internet. It is an inexpensive deworming medicine made for animals, and many people with cancer have read stories of patients who took it and recovered. This article explains what fenbendazole is, how it acts on cancer cells in laboratory research, what has and has not been shown in people, and what is known about its side effects. Everything here comes from peer-reviewed studies, listed at the end.

What Fenbendazole Is

Fenbendazole belongs to the benzimidazole family of antiparasitic drugs. Veterinarians use it to treat worms in dogs, cats, horses and farm animals. Two close relatives, mebendazole and albendazole, are approved for treating parasites in people. Fenbendazole itself is not approved for human use by the U.S. Food and Drug Administration or the European Medicines Agency, so its behavior in the human body has not been studied the way an approved drug’s would be.¹

In a parasite, fenbendazole binds to a protein called tubulin. Tubulin builds microtubules, the internal scaffolding a cell uses to hold its shape, move materials and pull its chromosomes apart when it divides. Disrupt that scaffolding and the parasite starves and dies. Cancer researchers became interested because cancer cells also depend heavily on microtubules, which is the same target used by some standard chemotherapy drugs.

How Fenbendazole Acts on Cancer Cells

Laboratory studies describe several separate actions. That matters, because a compound that hits a cancer cell in more than one place gives the cell fewer escape routes.

1. It loosens the cell’s scaffolding

In human lung cancer cells, fenbendazole acted as a moderate microtubule destabilizer. Cells stalled in the middle of division and then died.² “Moderate” is the key word: it disturbs microtubules less forcefully than chemotherapy drugs such as vincristine, which may help explain why normal cells in these experiments tolerated it better.

2. It switches on p53, the cell’s emergency brake

The p53 protein is often called the guardian of the genome. When a cell is badly damaged, p53 tells it to stop dividing or to die. In the same lung cancer study, fenbendazole raised p53 activity and moved p53 into the mitochondria, where it can trigger cell death directly.²

3. It cuts the cancer cell’s sugar supply

Many cancers burn glucose at a very high rate, a pattern known as the Warburg effect. Fenbendazole reduced the number of glucose transporters on the surface of cancer cells and lowered hexokinase II, the enzyme that takes the first step in breaking glucose down.² With less fuel coming in, the cancer cell is under metabolic stress.

4. It triggers an inflammatory form of cell death (2025 research from China)

A 2025 study from China found that fenbendazole slowed the growth of breast cancer in mice by causing pyroptosis, a form of cell death in which the cancer cell swells and bursts. The trigger again ran through hexokinase II: by blocking the cancer’s sugar metabolism, fenbendazole set off a chain through two proteins called caspase-3 and gasdermin E. The authors describe this as a new link between cancer metabolism and cancer cell death.³ Pyroptosis is of particular interest because a bursting cancer cell releases signals that can alert the immune system.

5. It works in some drug-resistant cells (research from Korea)

Researchers in Korea tested fenbendazole against colorectal cancer cells that had become resistant to 5-fluorouracil, a backbone chemotherapy drug for colon cancer. Fenbendazole killed the resistant cells, worked better than albendazole, and did so without needing p53, which matters because many advanced cancers have lost working p53.⁴

What the Animal Studies Show

Animal results are mixed, and the mix is informative. The first hint came by accident. At a U.S. laboratory in 2008, mice carrying human lymphoma were given fenbendazole to control a parasite outbreak. Their tumors grew more slowly, but only when fenbendazole was combined with supplementary vitamins. Neither fenbendazole alone nor the vitamins alone had the same effect.⁵

A 2013 study from Yale gave fenbendazole to mice with breast tumors. It killed the cancer cells in the dish at high concentrations, but on its own it did not slow tumor growth in the animals.⁶ The 2025 Chinese pyroptosis study, by contrast, did show slower tumor growth in mice.³ Differences in dose, the cancer model and how the drug was given likely explain the gap. The pattern so far suggests fenbendazole may work best as one part of a combination rather than alone.

How Far Fenbendazole Has Been Studied in People

No clinical trial of fenbendazole in people with cancer has been completed. The human evidence consists of individual case reports and personal accounts. Fenbendazole’s popularity grew from the story of an American patient with small-cell lung cancer who credited it for his recovery. He was also receiving treatment in a clinical trial at the time, so the effect of fenbendazole cannot be separated from the effect of his other treatment.

In 2025, a case series in the journal Case Reports in Oncology described three patients with advanced breast cancer, prostate cancer and melanoma who reached remission after adding fenbendazole to other therapies. That paper was widely shared. In January 2026, the publisher and editor retracted it after concerns that the first author had not declared a conflict of interest: at the time of submission he offered services related to the topic of the study.⁷ Anyone reading older articles or social media posts that cite this case series should know it has been withdrawn.

A further challenge is absorption. Fenbendazole dissolves poorly in water, and only a small fraction of a swallowed dose reaches the bloodstream. A 2024 review in Anticancer Research concluded that clinical trials are needed to establish whether it works in people with cancer, at what dose, and how well it is tolerated, and it discussed ways researchers are trying to improve absorption.¹

Known Side Effects and Drug Interactions

Liver injury. The best-documented side effect in people is liver injury. A report from Japan described a woman with advanced lung cancer, receiving immunotherapy, who took fenbendazole on her own after reading about it on social media and developed significant liver injury. Her liver tests returned to normal after she stopped it.⁸ Liver enzymes are the measurement to watch with this drug.

Product quality. Fenbendazole products are made and labeled for animals. They are not manufactured or tested to the standards of human medicines.

Drug interactions. Fenbendazole is processed by the liver. Its interactions with cancer drugs and other human medicines have not been formally studied, which is especially relevant for people receiving chemotherapy, targeted drugs or immunotherapy that also load the liver.

Fenbendazole, Mebendazole and Albendazole: What Is the Difference?

All three are benzimidazoles and share the same basic action on tubulin. The practical difference is regulatory: mebendazole and albendazole are approved human medicines, manufactured to pharmaceutical standards, and mebendazole has been tested in small early-phase cancer trials. Fenbendazole has the larger following online but the thinner human record. Laboratory comparisons show the three are not identical, and results with one should not be assumed for the others.

Where Fenbendazole Fits in an Integrative Approach

The most useful way to think about fenbendazole is by pathway rather than by product. Its documented actions fall on three cancer pathways: cell division (microtubules), the p53 stress response, and glucose metabolism. A cancer that relies heavily on glucose, or that has been shown on testing to be sensitive to microtubule disruption, is the kind of cancer where this family of drugs makes biological sense.

Functional testing can answer this more directly. Chemosensitivity testing, offered by laboratories in Europe and elsewhere, exposes a patient’s own living cancer cells to chemotherapy drugs, repurposed drugs and natural compounds, and reports which ones affect them. Benzimidazoles are among the compounds some of these laboratories test. Our book, The New Reality of Cancer, explains how this testing works and how its results can be organized into a plan. For a drug that acts on different pathways, read our article on ivermectin and cancer.

Frequently Asked Questions

Is fenbendazole approved for humans?

No. It is approved only for animals. Its relatives mebendazole and albendazole are approved for parasitic infections in people.

Does fenbendazole kill cancer cells?

In laboratory studies, yes. It kills several types of cancer cells, including some resistant to chemotherapy, through at least four mechanisms. Whether it does so in people has not been tested in a clinical trial.

Was the 2025 fenbendazole case series retracted?

Yes. The three-patient case series published in Case Reports in Oncology in May 2025 was retracted in January 2026 over an undeclared conflict of interest.

What is the main side effect of fenbendazole?

Liver injury is the most clearly documented side effect in people, including in a patient receiving immunotherapy.

---

More articles on repurposed drugs for cancer and all articles.

References

1. Nguyen J, Nguyen TQ, Han B, Hoang BX. Oral fenbendazole for cancer therapy in humans and animals. Anticancer Research. 2024;44(9):3725–3735. doi:10.21873/anticanres.17197
2. Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8:11926. doi:10.1038/s41598-018-30158-6
3. Pan T, Jin S, Huang X, Xin X, Xing Q, Yang W, Dong J, Li L. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway. Frontiers in Pharmacology. 2025;16:1596694. doi:10.3389/fphar.2025.1596694
4. Park D, Lee JH, Yoon SP. Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. Korean Journal of Physiology and Pharmacology. 2022;26(5):377–387.
5. Gao P, Dang CV, Watson J. Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science. 2008;47(6):37–40.
6. Duan Q, Liu Y, Rockwell S. Fenbendazole as a potential anticancer drug. Anticancer Research. 2013;33(2):355–362.
7. Retraction statement: Fenbendazole as an anticancer agent? A case series of self-administration in three patients. Case Reports in Oncology. 2026;19(1):169. Original article: Case Rep Oncol. 2025;18:856–863. doi:10.1159/000546362
8. Yamaguchi T, Shimizu J, Oya Y, Horio Y, Hida T. Drug-induced liver injury in a patient with nonsmall cell lung cancer after the self-administration of fenbendazole based on social media information. Case Reports in Oncology. 2021;14(2):886–891. doi:10.1159/000516276

This article is for education only. It is not medical advice and does not diagnose or treat any condition. Cancer Expert MD has no financial relationship with any laboratory, drug maker, supplement company, clinic or hospital.